Antineoplastics
1
Reactions 1351 - 14 May 2011 S Antineoplastics Interstitial lung disease: 4 case reports A retrospective study identified four patients who developed interstitial lung disease during treatment with standard chemotherapy with FOLFOX (fluorouracil + calcium levofolinate + oxaliplatin), FOLFIRI (fluorouracil + calcium levofolinate + irinotecan) or XELOX (capecitabine + oxaliplatin) and bevacizumab for metastatic colorectal cancer [routes and dosages not stated]. A 58-year-old man, who had previously received FOLFOX + bevacizumab, started receiving FOLFIRI + bevacizumab. Five days after his last dose following chemotherapy cycle 5, he presented with fever. A chest CT showed ground-glass opacities and an organising pneumonia pattern. The grade of ILD according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was grade 3. He was treated with high-dose methylprednisolone followed by prednisolone and his symptoms improved. One month later, he received XELOX + bevacizumab. On day 21 of therapy, he complained of fever. A chest x-ray showed infiltration at the right upper lung. He received antibiotics, but his symptoms did not disappear. He received steroid therapy and his symptoms improved. He was diagnosed with ILD recurrence induced by XELOX + bevacizumab. A 70-year-old man, who had previously received FOLFOX + capecitabine, started receiving FOLFIRI + bevacizumab. Eight days after his last dose following chemotherapy cycle 5, he presented with fever. A chest CT showed ground-glass opacities and an acute interstitial pneumonia pattern. The grade of ILD according to the CTCAE v3.0 was grade 4. He was treated with high-dose methylprednisolone followed by prednisolone and his symptoms improved. A 72-year-old man started receiving FOLFOX + bevacizumab. Two days after his last dose following chemotherapy cycle 15, he presented with fever. A chest CT showed ground-glass opacities and an organising pneumonia pattern. The grade of ILD according to the CTCAE v3.0 was grade 2. He was treated with high-dose methylprednisolone followed by prednisolone and his symptoms improved. A 59-year-old man, who had previously received XELOX, started receiving FOLFOX + bevacizumab. Two days after his last dose following chemotherapy cycle 9, he presented with fever. A chest CT showed ground-glass opacities and an idiopathic pulmonary fibrosis pattern. The grade of ILD according to the CTCAE v3.0 was grade 3. He was treated with high-dose methylprednisolone followed by prednisolone and ciclosporin and his symptoms improved. Usui K, et al. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Japanese Journal of Clinical Oncology 41: 498-502, No. 4, Apr 2011. Available from: URL: http://dx.doi.org/10.1093/jjco/hyr006 - Japan 803054186 1 Reactions 14 May 2011 No. 1351 0114-9954/10/1351-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1351 - 14 May 2011
SAntineoplastics
Interstitial lung disease: 4 case reportsA retrospective study identified four patients who
developed interstitial lung disease during treatment withstandard chemotherapy with FOLFOX (fluorouracil +calcium levofolinate + oxaliplatin), FOLFIRI (fluorouracil +calcium levofolinate + irinotecan) or XELOX (capecitabine+ oxaliplatin) and bevacizumab for metastatic colorectalcancer [routes and dosages not stated].
A 58-year-old man, who had previously receivedFOLFOX + bevacizumab, started receiving FOLFIRI +bevacizumab. Five days after his last dose followingchemotherapy cycle 5, he presented with fever. A chest CTshowed ground-glass opacities and an organisingpneumonia pattern. The grade of ILD according to theCommon Terminology Criteria for Adverse Events (CTCAE)v3.0 was grade 3. He was treated with high-dosemethylprednisolone followed by prednisolone and hissymptoms improved. One month later, he received XELOX+ bevacizumab. On day 21 of therapy, he complained offever. A chest x-ray showed infiltration at the right upperlung. He received antibiotics, but his symptoms did notdisappear. He received steroid therapy and his symptomsimproved. He was diagnosed with ILD recurrence inducedby XELOX + bevacizumab.
A 70-year-old man, who had previously receivedFOLFOX + capecitabine, started receiving FOLFIRI +bevacizumab. Eight days after his last dose followingchemotherapy cycle 5, he presented with fever. A chest CTshowed ground-glass opacities and an acute interstitialpneumonia pattern. The grade of ILD according to theCTCAE v3.0 was grade 4. He was treated with high-dosemethylprednisolone followed by prednisolone and hissymptoms improved.
A 72-year-old man started receiving FOLFOX +bevacizumab. Two days after his last dose followingchemotherapy cycle 15, he presented with fever. A chestCT showed ground-glass opacities and an organisingpneumonia pattern. The grade of ILD according to theCTCAE v3.0 was grade 2. He was treated with high-dosemethylprednisolone followed by prednisolone and hissymptoms improved.
A 59-year-old man, who had previously received XELOX,started receiving FOLFOX + bevacizumab. Two days afterhis last dose following chemotherapy cycle 9, he presentedwith fever. A chest CT showed ground-glass opacities andan idiopathic pulmonary fibrosis pattern. The grade of ILDaccording to the CTCAE v3.0 was grade 3. He was treatedwith high-dose methylprednisolone followed byprednisolone and ciclosporin and his symptoms improved.Usui K, et al. Interstitial lung disease during chemotherapy combined withoxaliplatin and/or bevacizumab in advanced colorectal cancer patients. JapaneseJournal of Clinical Oncology 41: 498-502, No. 4, Apr 2011. Available from: URL:http://dx.doi.org/10.1093/jjco/hyr006 - Japan 803054186
1
Reactions 14 May 2011 No. 13510114-9954/10/1351-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
